A biopharmaceutical firm has conducted trials using its innovative therapy involving stem cells on 148 participants aged between 70 and 85. Each individual received a one-time infusion of mesenchymal stem cells sourced from donated bone marrow. After a duration of nine months, those who underwent the treatment exhibited an average improvement of 63 meters in a six-minute walking test compared to the control group, marking a significant enhancement of approximately 20%. Additionally, their overall physical well-being demonstrated notable advancements. Mesenchymal stem cells possess the unique ability to transform into various tissue types and to secrete anti-inflammatory substances. Researchers theorize that this therapy may alleviate inflammation surrounding small blood vessels, potentially leading to enhanced physical capabilities. The syndrome of frailty is often characterized by diminished strength, reduced stamina, and slower recovery times following illnesses or falls. It is estimated to impact between 10% and 25% of individuals over the age of 65, with more than a quarter of those aged 85 and above affected. Throughout the trial, no severe side effects were reported. However, the journey towards regulatory approval is still unclear, as frailty is not officially classified as a distinct disease. The company aims to gain approval by demonstrating that their therapy can lower the risk of falls or enhance survival rates post-surgery.
Informational material. 18+.
